The 20% rarest cancers account for approximately 35% of the deaths from cancer in the United States. As a result, a better understanding of the nature of these rare tumors is in the public health's best interest. We study sarcomas, rare cancers of connective tissue: bone, muscle, fat, cartilage, and the other tissues that hold us together. These are cancers that occur disproportionately in children, teens, and young adults, although different forms affect different age groups. In all, sarcomas account for less than 1% of all cancer in the United States. However, since they can arise from so many different tissues, there are 70 or more sarcoma subtypes. We are interested in finding new treatments for the people with these rare cancers, who do not benefit from research on more common cancers. We have identified two new combinations of drugs that may be useful for people with sarcoma. The first of these is A12, an """"""""insulin-like growth factor 1 receptor"""""""" inhibitor, and temsirolimus, an mTOR inhibitor. The second is a blocker of Hh (hedgehog) signaling, GDC-0449, which we are combining with a blocker of gamma secretase (RO4929097) [Notch pathway] in a novel study for people with recurrent sarcomas. We are seeking funding to perform this multi-center study, focusing on biopsies from patients on these two studies for biological correlates of blockade of these various pathways. These biopsies will help us determine would or would not benefit from such therapy. We will also use a software tool we have recently developed, called StudyTracker, to collect the data from the multiple participating centers on the GDC-0449/RO4929097 phase I-II study. With this information, we will be able to use tests of tumors to insure that the right person is receiving the right medication, with the best chance of getting a good result from that treatment. Without such testing, clinical trials are reduced to """"""""throwing darts""""""""-some people could benefit, but we will not understand why. This approach should lead to new and efficient means to treat patients with sarcomas and may also impact patients with more common cancers.

Public Health Relevance

This is a project to support correlative studies for two multicenter clinical trials of new drugs for patients with sarcomas. These novel approaches will improve the treatment options for this underserved group of patients with this rare family of cancers

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
High Impact Research and Research Infrastructure Programs (RC2)
Project #
1RC2CA148260-01
Application #
7854415
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (O9))
Program Officer
Timmer, William C
Project Start
2009-09-30
Project End
2011-08-31
Budget Start
2009-09-30
Budget End
2010-08-31
Support Year
1
Fiscal Year
2009
Total Cost
$1,168,124
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Palmerini, Emanuela; Maki, Robert G; Staals, Eric L et al. (2014) Primary angiosarcoma of bone: a retrospective analysis of 60 patients from 2 institutions. Am J Clin Oncol 37:528-34
Schwartz, Gary K; Tap, William D; Qin, Li-Xuan et al. (2013) Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol 14:371-82
Chen, Junwei; Guo, Tianhua; Zhang, Lei et al. (2012) CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers. Genes Chromosomes Cancer 51:186-95
Fields, Ryan C; Hameed, Meera; Qin, Li-Xuan et al. (2011) Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy. Ann Surg Oncol 18:328-36
Schöffski, P; Taron, M; Jimeno, J et al. (2011) Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur J Cancer 47:1006-12
Guo, Tianhua; Zhang, Lei; Chang, Ning-En et al. (2011) Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosomes Cancer 50:25-33
Balagula, Yevgeniy; Pulitzer, Melissa P; Maki, Robert G et al. (2011) Pigmentary changes in a patient treated with imatinib. J Drugs Dermatol 10:1062-6
Ho, Alan L; Schwartz, Gary K (2011) Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning? J Clin Oncol 29:4581-3
Daher, May; Lacouture, Mario E; Rathkopf, Dana et al. (2011) Case series of dermatologic events associated with the insulin-like growth factor receptor 1 inhibitor cixutumumab. J Clin Oncol 29:e638-40
Gounder, Mrinal M; Maki, Robert G (2011) Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 67 Suppl 1:S25-43

Showing the most recent 10 out of 16 publications